文献速递产科麻醉区域麻醉与超声气道管理

SOAP COVID-19登记研究:美国疫情初期分娩孕妇结局分析

The Society for Obstetric Anesthesia and Perinatology Coronavirus Disease 2019 Registry: An Analysis of Outcomes Among Pregnant Women Delivering During the Initial Severe Acute Respiratory Syndrome Coronavirus-2 Outbreak in the United States.
PubMed 文献 · Anesth Analg · 2021-01-01

该多中心队列研究比较了490例围产期SARS-CoV-2感染孕妇与964例对照的结局。调整混杂因素后,感染组早产风险增加(aOR 1.47),有症状者剖宫产、产后住院时间和早产风险更高。感染组椎管内分娩镇痛使用率更低,剖宫产全身麻醉率更高。

要点

  • 有症状SARS-CoV-2感染孕妇剖宫产(aOR 1.57)、产后住院时间延长(aOR 1.89)和早产(aOR 2.08)风险增加。
  • 无症状感染者与对照相比未发现上述不良结局增加。
  • 感染孕妇椎管内分娩镇痛使用率更低(aOR 0.52),剖宫产全身麻醉率更高(aOR 3.69)。

核心结论

  • 产科和新生儿结局差异主要由有症状的SARS-CoV-2感染孕妇驱动。
  • 感染孕妇椎管内分娩镇痛使用率较低,需进一步研究。

研究设计与样本

  • 多中心队列研究,纳入美国14家医疗中心2020年3月19日至5月31日的分娩病例。
  • 感染组490例(有症状176例,35.9%),对照组964例,按1:2比例随机抽样。
  • 采用广义估计方程分析,并做症状分层敏感性分析。

主要发现

  • 感染组早产(<37周)风险高于对照组:73例(14.8%)vs 98例(10.2%),aOR 1.47(95%CI 1.03-2.09)。
  • 有症状感染者剖宫产aOR 1.57(95%CI 1.09-2.27),产后住院时间延长aOR 1.89(95%CI 1.18-2.60),早产aOR 2.08(95%CI 1.29-3.36)。
  • 无症状感染者与对照组相比未见不良结局增加。
  • 感染组椎管内分娩镇痛使用率更低:aOR 0.52(95%CI 0.35-0.75)。
  • 感染组剖宫产全身麻醉率更高:aOR 3.69(95%CI 1.40-9.74),因产妇呼吸衰竭。

临床怎么用

  • 对有症状的SARS-CoV-2感染孕妇应加强早产和剖宫产风险评估。
  • 感染孕妇椎管内分娩镇痛使用率偏低,需关注镇痛可及性与安全防护。
  • 剖宫产全身麻醉率较高与呼吸衰竭相关,应做好气道与呼吸支持准备。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early reports associating severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with adverse pregnancy outcomes were biased by including only women with severe disease without controls. The Society for Obstetric Anesthesia and Perinatology (SOAP) coronavirus disease 2019 (COVID-19) registry was created to compare peripartum outcomes and anesthetic utilization in women with and without SARS-CoV-2 infection delivering at institutions with widespread testing. METHODS: Deliveries from 14 US medical centers, from March 19 to May 31, 2020, were included. Peripartum infection was defined as a positive SARS-CoV-2 polymerase chain reaction test within 14 days of delivery. Consecutive SARS-CoV-2-infected patients with randomly selected control patients were sampled (1:2 ratio) with controls delivering during the same day without a positive test. Outcomes were obstetric (eg, delivery mode, hypertensive disorders of pregnancy, and delivery <37 weeks), an adverse neonatal outcome composite measure (primary), and anesthetic utilization (eg, neuraxial labor analgesia and anesthesia). Outcomes were analyzed using generalized estimating equations to account for clustering within centers. Sensitivity analyses compared symptomatic and asymptomatic patients to controls. RESULTS: One thousand four hundred fifty four peripartum women were included: 490 with SARS-CoV-2 infection (176 [35.9%] symptomatic) and 964 were controls. SARS-CoV-2 patients were slightly younger, more likely nonnulliparous, nonwhite, and Hispanic than controls. They were more likely to have diabetes, obesity, or cardiac disease and less likely to have autoimmune disease. After adjustment for confounders, individuals experiencing SARS-CoV-2 infection exhibited an increased risk for delivery <37 weeks of gestation compared to controls, 73 (14.8%) vs 98 (10.2%) (adjusted odds ratio [aOR], 1.47; 95% confidence interval [CI], 1.03-2.09). Effect estimates for other obstetric outcomes and the neonatal composite outcome measure were not meaningfully different between SARS-CoV-2 patients versus controls. In sensitivity analyses, compared to controls, symptomatic SARS-CoV-2 patients exhibited increases in cesarean delivery (aOR, 1.57; 95% CI, 1.09-2.27), postpartum length of stay (aOR, 1.89; 95% CI, 1.18-2.60), and delivery <37 weeks of gestation (aOR, 2.08; 95% CI, 1.29-3.36). These adverse outcomes were not found in asymptomatic women versus controls. SARS-CoV-2 patients (asymptomatic and symptomatic) were less likely to receive neuraxial labor analgesia (aOR, 0.52; 95% CI, 0.35-0.75) and more likely to receive general anesthesia for cesarean delivery (aOR, 3.69; 95% CI, 1.40-9.74) due to maternal respiratory failure. CONCLUSIONS: In this large, multicenter US cohort study of women with and without peripartum SARS-CoV-2 infection, differences in obstetric and neonatal outcomes seem to be mostly driven by symptomatic patients. Lower utilization of neuraxial analgesia in laboring patients with asymptomatic or symptomatic infection compared to patients without infection requires further investigation.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Katz D, Bateman BT, Kjaer K, et al. The Society for Obstetric Anesthesia and Perinatology Coronavirus Disease 2019 Registry: An Analysis of Outcomes Among Pregnant Women Delivering During the Initial Severe Acute Respiratory Syndrome Coronavirus-2 Outbreak in the United States. Anesth Analg. 2021. PMID: 33830956. doi:10.1213/ANE.0000000000005592

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。